Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?

Nature Reviews Clinical Oncology

Volumn 6, Issue 10, 2009, Pages 562-563

  Johnson, Faye M ^a   Glisson, Bonnie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; ETHNIC DIFFERENCE; FEBRILE NEUTROPENIA; HUMAN; LUNG SMALL CELL CANCER; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DIARRHEA; DRUG THERAPY; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ETHNIC GROUPS; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GLUCURONOSYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; NEUTROPENIA; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; THERAPEUTIC EQUIVALENCY; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349774613     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.141     Document Type: Article

References (10)

1. Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85-91 (2002).
2. Hanna, N. et al. Randomized phase III trial comparing irinotecan/ cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24, 2038-2043 (2006).
3. Lara, P. N., Jr et al. Phase III trial of Irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG SO124. J. Clin. Oncol. 27, 2530-2535 (2009).
4. Hermes, A. et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial. J. Clin. Oncol. 26, 4261-4267 (2008).
5. Schmittel, A. H. Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial [abstract]. ASCO Meeting Abstracts 27, 8029 (2009).
6. Palomaki, G. E., Bradley, L. A., Douglas, M. P., Kolor, K. & Dotson, W. D. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med. 11, 21-34 (2009).
7. Gandara, D. R. et al. Japanese-Us common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27, 3540-3546 (2009).
8. Glisson, B. S. Recurrent small cell lung cancer: Update. Semin. Oncol. 30, 72-78 (2003).
9. Inoue, A. et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer study Group Trial 0402. J. Clin. Oncol. 26, 5401-5406 (2008).
10. Eckardt, J. R. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086-2092 (2007).